Plain-English difference
DSIP is an investigational peptide; glycine is a widely available amino acid
DSIP is short for delta sleep-inducing peptide and is also called emideltide. It appears in peptide, recovery, and sleep marketing, but its name is not proof that it treats insomnia. Glycine is a nonessential amino acid involved in protein structure, neurotransmission, and glutathione synthesis. It may be sold as a single-ingredient powder or capsule, or appear in collagen, protein, GlyNAC, and sleep blends. Comparing the front-label names alone misses route, evidence, formulation, quality, and clinical-context differences.
- A DSIP question should include the proposed route, human evidence for that route, clinician review, pharmacy identity, patient-specific labeling, storage, adverse-event support, and current compounding-policy status.
- A glycine question should identify whether the product is glycine alone, collagen, protein powder, GlyNAC, or a multi-ingredient blend and should review the complete Supplement Facts panel.
- Compounded medications are individualized prescriptions when lawful and appropriate; they are not FDA-approved finished drug products.
What the studies can and cannot answer
Neither evidence base supports a universal sleep result or an online protocol
A small double-blind study of 16 people with chronic insomnia found weak objective signals after intravenous DSIP, but the authors concluded that short-term DSIP was not likely to provide major therapeutic benefit. A 2024 systematic review of glycine administration in adults reported some positive nervous-system findings, including sleep findings in healthy adults, while specifically noting small sleep studies and a high risk of bias. Those findings do not establish which product is better, predict an individual response, validate a consumer peptide route, or replace an insomnia evaluation.
- Do not turn the words “sleep-inducing peptide” into proof of efficacy, an approved indication, or a safe dose and route.
- Do not treat glycine-alone evidence as evidence for collagen, GlyNAC, a proprietary sleep blend, or every amount sold online.
- Head-to-head DSIP-versus-glycine evidence is not established; marketing comparisons should not be presented as comparative clinical results.
Diagnosis before a sleep stack
The sleep pattern and its cause may matter more than either product
Insomnia symptoms can reflect inconsistent sleep opportunity, shift work, jet lag, caffeine or alcohol timing, anxiety or depression, pain, reflux, menopause symptoms, thyroid disease, anemia, restless legs, sleep apnea, medicine effects, or another sleep disorder. Loud snoring, witnessed breathing pauses, waking gasping, morning headaches, and dangerous daytime sleepiness deserve prompt evaluation rather than a larger supplement or peptide stack. Chronic insomnia also deserves evidence-based assessment instead of repeated product switching.
- Track sleep and wake times, awakenings, naps, caffeine and alcohol timing, symptoms, medicines, supplements, and next-day function before the visit.
- Review sedatives, antihistamines, antidepressants, stimulants, opioids, seizure medicines, alcohol, cannabis, melatonin, magnesium, valerian, L-theanine, collagen, GlyNAC, and combination sleep products.
- Seek urgent care for trouble breathing, chest pain, fainting, severe confusion, suicidal thoughts, suspected overdose, or severe sleepiness while driving or operating equipment.
July 2026 FDA context
PCAC review is not FDA approval or guaranteed compounding access
FDA materials for the July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting include emideltide/DSIP in a section 503A bulk-drug-substance discussion. The scheduled advisory review is not approval of DSIP as a finished drug, not an insomnia indication, not a dosing recommendation, and not a promise that a compounded product will remain or become available. Committee recommendations are advisory; FDA makes final determinations after considering that input and completing its reviews.
- Do not rely on seller language such as “FDA July release,” “approved sleep peptide,” or “PCAC-cleared DSIP.”
- A research-use label does not make a product appropriate for human use, and a consumer peptide checkout page is not a substitute for a lawful prescription and licensed pharmacy.
- Dietary supplements are regulated differently from drugs; glycine availability does not mean FDA preapproved each product for sleep treatment, quality, or effectiveness.
Safety and product-quality review
Route, ingredients, health history, and seller behavior change the risk
DSIP adds route-specific, sterility, pharmacy, legal-status, and follow-up questions that do not apply to a basic oral supplement in the same way. Glycine avoids injection-specific risks but can be duplicated across powders, collagen, protein products, GlyNAC, and proprietary blends. Either can complicate interpretation when combined with sedating substances or multiple sleep products. Pregnancy or breastfeeding, kidney or liver disease, psychiatric or seizure history, medication changes, planned procedures, and safety-sensitive work should be reviewed before adding a new product.
- For a supplement, prefer a complete label, lot and manufacturer identity, realistic claims, third-party quality information, warnings, and an adverse-event contact path.
- For a compounded prescription, ask which licensed clinician reviewed it, which licensed pharmacy dispenses it, what appears on the patient-specific label, and who handles side effects and refills.
- Stop and seek appropriate help for severe allergic symptoms, breathing trouble, fainting, severe confusion, persistent vomiting, infection signs after an injection, or rapidly worsening symptoms.